126 related articles for article (PubMed ID: 1652947)
1. HIV-1 proteinase is required for synthesis of pro-viral DNA.
Baboonian C; Dalgleish A; Bountiff L; Gross J; Oroszlan S; Rickett G; Smith-Burchnell C; Troke P; Merson J
Biochem Biophys Res Commun; 1991 Aug; 179(1):17-24. PubMed ID: 1652947
[TBL] [Abstract][Full Text] [Related]
2. Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease.
Jacobsen H; Ahlborn-Laake L; Gugel R; Mous J
J Virol; 1992 Aug; 66(8):5087-91. PubMed ID: 1378515
[TBL] [Abstract][Full Text] [Related]
3. Modified oligopeptides designed to interact with the HIV-1 proteinase inhibit viral replication.
Grinde B; Hungnes O; Tjøtta E
Arch Virol; 1990; 114(3-4):167-73. PubMed ID: 2241573
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues.
Meek TD; Lambert DM; Dreyer GB; Carr TJ; Tomaszek TA; Moore ML; Strickler JE; Debouck C; Hyland LJ; Matthews TJ
Nature; 1990 Jan; 343(6253):90-2. PubMed ID: 1688646
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of HIV by an anti-HIV protease synthetic peptide blocks an early step of viral replication.
Venaud S; Yahi N; Fehrentz JL; Guettari N; Nisato D; Hirsch I; Chermann JC
Res Virol; 1992; 143(5):311-9. PubMed ID: 1480823
[TBL] [Abstract][Full Text] [Related]
6. Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection.
Lambert DM; Bartus H; Fernandez AV; Bratby-Anders C; Leary JJ; Dreyer GB; Metcalf BW; Petteway SR
Antiviral Res; 1993 Aug; 21(4):327-42. PubMed ID: 7692816
[TBL] [Abstract][Full Text] [Related]
7. Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity.
Rosé JR; Babé LM; Craik CS
J Virol; 1995 May; 69(5):2751-8. PubMed ID: 7535864
[TBL] [Abstract][Full Text] [Related]
8. Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro.
Panther LA; Coombs RW; Aung SA; dela Rosa C; Gretch D; Corey L
J Med Virol; 1999 Jun; 58(2):165-73. PubMed ID: 10335865
[TBL] [Abstract][Full Text] [Related]
9. Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.
Nagy K; Young M; Baboonian C; Merson J; Whittle P; Oroszlan S
J Virol; 1994 Feb; 68(2):757-65. PubMed ID: 8289379
[TBL] [Abstract][Full Text] [Related]
10. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.
McQuade TJ; Tomasselli AG; Liu L; Karacostas V; Moss B; Sawyer TK; Heinrikson RL; Tarpley WG
Science; 1990 Jan; 247(4941):454-6. PubMed ID: 2405486
[TBL] [Abstract][Full Text] [Related]
11. Comparative properties of feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteinases prepared by total chemical synthesis.
Schnölzer M; Rackwitz HR; Gustchina A; Laco GS; Wlodawer A; Elder JH; Kent SB
Virology; 1996 Oct; 224(1):268-75. PubMed ID: 8862421
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins.
Tözsér J; Bláha I; Copeland TD; Wondrak EM; Oroszlan S
FEBS Lett; 1991 Apr; 281(1-2):77-80. PubMed ID: 2015912
[TBL] [Abstract][Full Text] [Related]
13. The proteinase inhibitor pepstatin A inhibits formation of reverse transcriptase in H9 cells infected with human immunodeficiency virus 1.
Grinde B; Hungnes O; Tjøtta E
AIDS Res Hum Retroviruses; 1989 Jun; 5(3):269-74. PubMed ID: 2471542
[TBL] [Abstract][Full Text] [Related]
14. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 protease inhibitors containing statine: inhibitory potency and antiviral activity.
Fehrentz JA; Chomier B; Bignon E; Venaud S; Chermann JC; Nisato D
Biochem Biophys Res Commun; 1992 Oct; 188(2):865-72. PubMed ID: 1445327
[TBL] [Abstract][Full Text] [Related]
16. CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity.
Alteri E; Bold G; Cozens R; Faessler A; Klimkait T; Lang M; Lazdins J; Poncioni B; Roesel JL; Schneider P
Antimicrob Agents Chemother; 1993 Oct; 37(10):2087-92. PubMed ID: 8257128
[TBL] [Abstract][Full Text] [Related]
17. Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system.
Lin YC; Brik A; de Parseval A; Tam K; Torbett BE; Wong CH; Elder JH
J Virol; 2006 Aug; 80(16):7832-43. PubMed ID: 16873240
[TBL] [Abstract][Full Text] [Related]
18. Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase.
Kräusslich HG; Ochsenbauer C; Traenckner AM; Mergener K; Fäcke M; Gelderblom HR; Bosch V
Virology; 1993 Feb; 192(2):605-17. PubMed ID: 8421902
[TBL] [Abstract][Full Text] [Related]
19. Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.
Wu X; Liu H; Xiao H; Kappes JC
Virology; 1996 May; 219(1):307-13. PubMed ID: 8623547
[TBL] [Abstract][Full Text] [Related]
20. Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.
Goodenow MM; Bloom G; Rose SL; Pomeroy SM; O'Brien PO; Perez EE; Sleasman JW; Dunn BM
Virology; 2002 Jan; 292(1):137-49. PubMed ID: 11878916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
